Focused On-demand Library for Protein N-lysine methyltransferase METTL21A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8WXB1

UPID:

MT21A_HUMAN

Alternative names:

HSPA lysine methyltransferase; HSPA-KMT; Hepatocellular carcinoma-associated antigen 557b; Methyltransferase-like protein 21A

Alternative UPACC:

Q8WXB1; Q53RV0; Q8N1Z9; Q96GH6

Background:

Protein N-lysine methyltransferase METTL21A, also known as HSPA lysine methyltransferase, plays a pivotal role in post-translational modifications, specifically targeting the heat shock protein 70 (HSP70) family. It is responsible for the selective trimethylation of lysine residues in HSPA1, HSPA2, HSPA5, HSPA6, and HSPA8, which are crucial for cellular stress responses and protein homeostasis.

Therapeutic significance:

Understanding the role of Protein N-lysine methyltransferase METTL21A could open doors to potential therapeutic strategies. Its precise function in modulating the HSP70 family suggests a significant impact on cellular resilience and disease mechanisms.